Galectin-3 is an independent predictor of survival in systemic sclerosis

Faludi, Réka; Nagy, Gabriella; Tökés-Füzesi, Margit; Kovács, Krisztina; Czirják, László; Komócsi, András

doi:10.1016/j.ijcard.2016.12.140

Cited by 27 publications

(23 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the serum galectin-3 levels were higher in inflammatory disorders patients with systemic sclerosis, Behçet's disease, and systemic lupus erythematosus. 11,12,19 Serum Gal-3 concentrations were found to be also increased in patients with rheumatoid arthritis. 13 Our study first found that serum galectin-3 levels were higher in patients with AS than healthy controls.…”

Section: Discussionmentioning

confidence: 96%

“…These studies indicated that serum galectin‐3 may be a marker of active fibrosis. In addition, the serum galectin‐3 levels were higher in inflammatory disorders patients with systemic sclerosis, Behçet’s disease, and systemic lupus erythematosus . Serum Gal‐3 concentrations were found to be also increased in patients with rheumatoid arthritis .…”

Section: Discussionmentioning

confidence: 97%

“…Previous studies have shown that increased galectin‐3 expression was observed in various cancer cells . Recently, the increased expression of galectin‐3 has been suggested in autoimmune diseases such as systemic sclerosis, Behcet’s disease, and rheumatoid arthritis ; these studies indicated that serum galectin‐3 might be associated with the pathogenesis and progression of rheumatic disease. Therefore, the aim of our study was to assess the potential correlation of serum galectin‐3 levels and ASDAS index in patients with AS.…”

Section: Introductionmentioning

confidence: 98%

See 2 more Smart Citations

Serum galectin‐3 concentrations in patients with ankylosing spondylitis

Cao

Wang

Gao

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

ObjectiveThe aim of our study was to assess potential correlations between serum galectin‐3 concentrations and Ankylosing Spondylitis Disease Activity (ASDAS) index in patients with ankylosing spondylitis (AS).MethodsA total of 112 patients with AS were included, and 130 healthy subjects were considered as controls. We collected the detailed medical history, and ASDAS index was used to assess the disease severity in patients with AS.ResultsThe serum galectin concentrations were higher in AS patients compared to the health groups (14.1 ± 9.6 vs 9.2 ± 3.7, P < 0.001). The correlation analysis showed that serum galectin concentrations were significantly positively correlated with C‐reactive protein and erythrocyte sedimentation rate (r = 0.369, P < 0.001; r = 0.240, P = 0.011). In addition, the positively correlation of serum galectin‐3 with global pain index (r = 0.238, P = 0.011) was observed in AS patients. A significant positively correlation between serum galectin and ASDAS index in AS patients was found (r = 0.367; P < 0.001). In multiple linear regression analysis, the results indicated that increased serum galectin still was correlated with ASDAS index (r = 0.322, P < 0.001) in patients with AS.ConclusionsSerum galectin concentrations were found to be correlated with ASDAS index in patients with AS.

show abstract

Section: Discussionmentioning

confidence: 96%

Section: Discussionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 98%

See 1 more Smart Citation

Serum galectin‐3 concentrations in patients with ankylosing spondylitis

Cao

Wang

Gao

et al. 2019

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…5 Faludi et al suggested galectin-3 is an independent predictor of all-cause and cardiovascular mortality in systemic sclerosis (SSc) and its levels were in positive correlation with erythrocyte sedimentation rate (ESR) and CRP. 17 Shi et al found that anti-galectin-3 antibody of SLE patients was significantly higher as compared to healthy individuals. Additionally, anti-galectin-3 antibody decreased with skin recovery and was strongly related to lupus cutaneous vasculitis.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, serum galectin‐3 was related to the level of C‐reactive protein (CRP) and G3BP was associated with joint destruction . Faludi et al suggested galectin‐3 is an independent predictor of all‐cause and cardiovascular mortality in systemic sclerosis (SSc) and its levels were in positive correlation with erythrocyte sedimentation rate (ESR) and CRP …”

Section: Discussionmentioning

confidence: 99%

Plasma galectin‐3 levels do not differ in systemic lupus erythematosus patients

et al. 2019

View full text Add to dashboard Cite

Objective To investigate the plasma galectin‐3 levels in systemic lupus erythematosus (SLE) patients and its relations with clinical and laboratory features. Methods A total of 180 subjects with 90 patients with SLE (8 male, 82 female, mean age 37.86 ± 13.98 years) and 90 healthy controls (8 male, 82 female, mean age 36.54 ± 10.89 years) were included. Plasma galectin‐3 levels were detected by enzyme‐linked immunosorbent assay (ELISA). Results There was no significant difference in age and gender distribution between SLE patients and healthy controls (both P > .05). Plasma galectin‐3 level was not significantly different between SLE patients and controls (P = .982) (P > .05). No significant difference was found regarding galectin‐3 levels between SLE with nephritis and those without nephritis (P > .05); no significant difference was found between less active SLE and more active SLE (P > .05). Galectin‐3 levels were inversely related to immune globulin M (r = −.303, P < .05), while no significant correlation between galectin‐3 levels and other quantitative laboratory parameters were observed (all P > .05). Conclusions In summary, plasma galectin‐3 level was not significantly different between SLE patients and controls (P = .982). Further studies are needed to elucidate the role of galectin‐3 in SLE.

show abstract

Altered serum level of metabolic and endothelial factors in patients with systemic sclerosis

et al. 2019

View full text Add to dashboard Cite

Systemic sclerosis (SSc) is a chronic connective tissue disease characterized by progressive fibrosis, vascular impairment and immune abnormalities. In recent years, adipokines (mediators synthetized by adipose tissue) have been indicated as a possible missing link in the pathogenesis of SSc. The aim of this study was to investigate the serum concentration of metabolic adipose tissue factors: adiponectin, resistin, leptin and endothelial proteins: endothelin-1, fractalkine and galectin-3 in patients with systemic sclerosis. The study included 100 patients with confirmed SSc diagnosis and 20 healthy individuals. The concentration of respective proteins was determined by enzyme-linked immunosorbent assay. The following markers showed statistically significant increased mean concentrations in patients with SSc in comparison to healthy control: resistin (13.41 vs 8.54 ng/mL; P = 0.0012), endothelin-1 (1.99 vs 1.31 pg/mL; P = 0.0072) and fractalkine (2.93 vs 1.68 ng/mL; P = 0.0007). Elevated serum levels of galectin-3 (4.54 vs 3.26 ng/mL; P = 0.0672) and leptin (19,542 vs 14,210 pg/mL; P = 0.1817) were observed. Decreased concentration of adiponectin was found in patients with SSc (5150 vs 8847 pg/mL; P = 0.0001). Fractalkine and galectin-3 levels were significantly higher in diffuse cutaneous SSc than limited cutaneous SSc subset (3.93 ng/mL vs 2.58 ng/mL, P = 0.0018; 6.86 ng/mL vs 3.78 ng/mL, P = 0.0008, respectively) and correlated positively with modified Rodnan Skin Score in total SSc patients (r = 0.376, P = 0.0009; r = 0.236, P = 0.018, respectively). In conclusion, an increased serum level of resistin associated with increased endothelin-1 and fractalkine level and decreased adiponectin level may indicate a significant role of the adipose tissue in the development and progression of vascular abnormalities in patients with systemic sclerosis. Fractalkine and galectin-3 may participate in promoting and exacerbating the fibrotic process in SSc.

show abstract

Galectin-3 is an independent predictor of survival in systemic sclerosis

Cited by 27 publications

References 23 publications

Serum galectin‐3 concentrations in patients with ankylosing spondylitis

Serum galectin‐3 concentrations in patients with ankylosing spondylitis

Plasma galectin‐3 levels do not differ in systemic lupus erythematosus patients

Altered serum level of metabolic and endothelial factors in patients with systemic sclerosis

Contact Info

Product

Resources

About